Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilzabrutinib in Relapsed Immune Thrombocytopenia
NCT03395210Phase 2Completed
- Sponsor
- Sanofi
- Start
- Mar 2018
- Primary completion
- Jan 2023
- Countries
- 8
01
Overview
A Phase 2 trial of rilzabrutinib in immune thrombocytopenia (ITP), sponsored by Sanofi. Started Mar 2018; status: completed.
02
Drugs
rilzabrutinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT03395210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03395210.